Viral vectors and host cells and methods of making and using...

Details Viral vectors and host cells and methods of making and using... Viral vectors and host cells and methods of making and using...

2004-05-07

2009-08-11

Li, Q. Janice (Department: 1633)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C536S023100, C435S320100

Reexamination Certificate

active

07572906

ABSTRACT:
The present invention provides a conditionally replicating viral vector, methods of making, modifying, propagating and selectively packaging, and using such a vector, isolated molecules of specified nucleotide and amino acid sequences relevant to such vectors, a pharmaceutical composition and a host cell comprising such a vector, the use of such a host cell to screen drugs. The methods include the prophylactic and therapeutic treatment of viral infection, in particular HIV infection, and, thus, are also directed to viral vaccines and the treatment of cancer, in particular cancer of viral etiology. Other methods include the use of such conditionally replicating viral vectors in gene therapy and other applications.

REFERENCES:
patent: 4650764 (1987-03-01), Temin et al.
patent: 4980289 (1990-12-01), Temin et al.
patent: 5144019 (1992-09-01), Rossi et al.
patent: 5180818 (1993-01-01), Cech et al.
patent: 5225337 (1993-07-01), Robertson et al.
patent: 5272262 (1993-12-01), Rossi et al.
patent: 5399346 (1995-03-01), Anderson et al.
patent: 5593972 (1997-01-01), Weiner et al.
patent: 5604114 (1997-02-01), Haseltine et al.
patent: 5646032 (1997-07-01), ter Meulen et al.
patent: 5665577 (1997-09-01), Sodroski et al.
patent: 5672510 (1997-09-01), Eglitis et al.
patent: 5712384 (1998-01-01), Symonds et al.
patent: 5716613 (1998-02-01), Guber et al.
patent: 5716826 (1998-02-01), Gruber et al.
patent: 5885806 (1999-03-01), Dropulic et al.
patent: 5888767 (1999-03-01), Dropulic et al.
patent: 5994136 (1999-11-01), Naldini et al.
patent: 6114141 (2000-09-01), Dropulic et al.
patent: 6140111 (2000-10-01), Riviere et al.
patent: 6168953 (2001-01-01), Dropulic et al.
patent: 6207426 (2001-03-01), Dropulic et al.
patent: 6218181 (2001-04-01), Verma et al.
patent: 6232120 (2001-05-01), Dropulic et al.
patent: 6410257 (2002-06-01), Dropulic et al.
patent: 6498033 (2002-12-01), Dropulic et al.
patent: 6544771 (2003-04-01), Riviere et al.
patent: 2006/0019393 (2006-01-01), Cannon et al.
patent: 52803/93 (1994-07-01), None
patent: 0 612 844 (1994-08-01), None
patent: 0 653 488 (1995-05-01), None
patent: 0 759 471 (1997-02-01), None
patent: WO 93/23569 (1993-11-01), None
patent: WO 94/01549 (1994-01-01), None
patent: WO 94/26877 (1994-11-01), None
patent: WO 95/04818 (1995-02-01), None
patent: WO-95/18854 (1995-07-01), None
patent: WO 95/21259 (1995-08-01), None
patent: WO 95/29241 (1995-11-01), None
patent: WO 95/30755 (1995-11-01), None
patent: WO 99/47660 (1999-09-01), None
Horvai et al. Scavenger receptor A gene regulatory elements target gene expression to macrophages and to foam cells of atherosclerotic lesions. PNAS, 1995. 92:5391-5395.
Fujita et al. Selective Inhibition of Human T-Lymphotrophic Virus Type I-Transformed Human T-Cell Growth by a tax-Targeted Conditionally Cytotoxic Recombinant Retrovirus. Blood, 1994: 2591-2596.
Kaye et al (cis-acting sequences involved in human immunodeficiency virus type 1 RNA packaging. Journal of Virology, 1995. 69(10):6588-92).
Horvai et al (PNAS, 1995; 5391-5395).
Fujita, et al (Blood, 1994. 2591-2596).
Sczakiel et al. Ann N Y Acad Sci Oct. 28, 1992;660:268-70.
Adachi et al. (1986).J Virol59:284-291.
Altman (1993).Proc Natl Acad Sci90:10898-10900.
Anderson (1992).Science256:808-813.
Baba T. et al. (1995).Science267:1823-1825.
Baltimore (1988).Nature325: 395-396.
Barr et al.Methods: A Companion to Methods in Enzymology4: 169-176.
Benson et al. (1993).J Exp Med177:1561-1566.
Buchschacher, Jr. et al. (1992).J Virol66:2731-2739.
Buchschacher, Jr. et al. (1992).Human Gene Ther3:391-397.
Buchschacher, Jr. et al. (1993).JAMA269:2880-2886.
Carroll et al. (1994).J Virol68:6047-6051.
Cech (1987).Science236:1532-1539.
Chen et al. (1992).Nuc Acids Res20:4581-4589.
Chen et al. (1992).Annals New York Academy of Sciences660:271-273.
Chowrira et al. Abstract and sequence alignment from WO 95/04818 (Feb. 1995).
Christopffersen et al. (1995).J. Med. Chem. 38:2023-2037.
Coffin (1992).Curr Top Microbiol Immunol176:143-164.
Coffin (1995).Science267:483-489.
Cohen (1995).Science268:1566.
Coombs et al. (1989).New Engl J Med321:1626-1631.
Cournoyer et al. (1993).Ann Rev Immunol11:297-329.
Crystal (1995).Science270:404-410.
Daniel M. et al. (1992).Science258:1938-1941.
Desrosiers R. (1994).AIDS Res&Human Retrovir10:331-332.
Dropulic et al. (1992).J Virol66:1432-1441.
Dropulic et al. (1993).Methods: A Companion to Methods in Enzymology5:43-49.
Dropulic et al. (1993).Antisense Research and Development3:87-94.
Dropulic et al. (1996).PNAS USA93:11103-1108.
Dropulic et al. (1994).Human Gene Ther5:927-939.
Dropulic et al. (1995).Gene Therapy and Molecular Medicine, Abst. No. C6-310,391 (Mar. 26-Apr. 1, 1995).
Freed et al. (1992).Proc Natl Acad Sci89:70-74.
Friedmann. (1989).Science244:1275-1281.
Gilboa et al. (1994).TIG10:139-144.
Hampel et al. (1990).Nuc Acids Res18:299-304.
Harada et al. (1985).Science229:563-566.
Harlow et al., Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory (1988) p. 1.
Haseloff et al. (1988).Nature334:585-591.
Haseloff et al. (1989).Gene82:43-52.
Ho et al., Nature (1995) 373:123-126.
Ho et al. (1989).New Engl J Med321:1621-1625.
Inoue et al. (1991).Proc Natl Acad Sci88:2278-2282.
James et al. (1992).Annals New York Academy of Sciences660:274-275.
Johnson V. et al, eds. (1990). “Quantitative Assays for Virus Infectivity,” In:Tech in HIV Res, Stockton Press, 71-76.
Johnston et al. (1993)Science260:1286-1293.
Kim et al. (1993).AIDS Res&Human Retrovir9:875-882.
Liska et al. (1994).J Gen Virol75:2955-2962.
Lusso et al. (1995).J Virol69:3712-3720.
Malim et al. (1992).J EXp Med176:1197-1201.
Marasco et al. (1993).Proc Natl Acad Sci90:7889-7893.
Matthews (1994).AIDS Res&Human Retrovir10:631-632.
Merigan T. (1991). “Treatment of AIDS with Combinations of Antiretroviral Agents,”Am J Med90 (Suppl. 4A):8S-17S.
Michael et al. (1994)J. Virol. 68(5):3163-3174.
Miller (1992).Nature357:455-460.
Mulligan (1993).Science260:929-931.
Myers et al. (1992).HIV Sequence Database, Los Alamos Nat Lab., 1-A-9 to 1-A-17 (Sep. 1992).
Nadlini L. et al. (1996). “In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector,”Science272:263-267.
Ohkawa et al. (1993)Proc. Natl. Acad. Sci. 90:11302-11306.
Ojwang et al. (1992).Proc Natl Acad Sci89:10802-10806.
Orkin and Motulsky (1995). “Report and recommendations of the panel to assess the NIH investment in research on gene therapy,” National Institute of Health.
Page et al. (1990).J Virol64:5270-5276.
Parolin et al. (1994).J Virol68:3888-3895.
Pathak et al. (1990).Proc Natl Acad Sci87:6024-6028.
Paulus W. et al. (1996).J Virol70:62-67.
Pearson et al. (1990).Proc Natl Acad Sci87:5079-5083.
Piatak et al.Science259:1749-1754.
Poznansky et al. (1991).J Virol65:532-536.
Preston et al. (1988).Science242:1168-1171.
Richardson et al. (1993).J Virol67:3997-4005.
Richardson et al. (1995).J Gen Virol76:691-696.
Richman D. (1992). “HIV Drug Resistance,”AIDS Res&Human Retrovir8:1065-1071.
Roberts et al. (1988).Science242:1171-1173.
Saag, et al. (1988).Nature334:440-444.
Saksela et al. (1994).Proc Natl Acad Sci91:1104-108.
Sarver et al. (1990).Science247:1222-1225.
Sarver et al. (1993).J NIH Res5L63-67.
Sarver et al. (1993).AIDS Res&Human Retrovir9:483-487.
Shin C.-K. et al. (1991). “Chimeric Human Immunodeficiency Virus Type 1/Type 2 Reverse Transcriptases Display Reversed Sensitivity to Nonnucleoside Analog Inhibitors,”PNAS88:9878-9882.
Stevenson et al. (1988).Cell53:483-496.
Sullenger et al. (1990).Cell63:601-608.
Sullenger et al. (1994).Science262:1566-1569.
Sun et al. (1994).Proc Natl Acad Sci91:9715-9718.
Sun et al., Proc. Nat'l. Acad. Sci. USA (1995) 92:7272-7276.
Symons (1992).Ann Rev Biochem61:641-671.
Technology Access Report, “Ribozymes for Treating Hepatitis C,” 17 (Feb. 1996).
Thierry et al. (1995).Proc Natl Acad Sci92:9742-9746.
Tisdale et al. (1993).Proc. Natl. Acad. Sci. 90:5653-5656.
Travers et al. (1995).Science268:1612-1615.
Ueda K. et al. (1986). Themdr1 Gene, Responsible for M

Affiliated with

Also associated with

Rating

Viral vectors and host cells and methods of making and using... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Viral vectors and host cells and methods of making and using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Viral vectors and host cells and methods of making and using... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4127352